Skip to main content

Drug Interactions between daunorubicin liposomal and Herzuma

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

DAUNOrubicin liposomal trastuzumab

Applies to: daunorubicin liposomal and Herzuma (trastuzumab)

GENERALLY AVOID: The use of trastuzumab and anthracyclines in combination has been associated with a high risk of cardiotoxicity. Trastuzumab and agents in the anthracycline class are individually cardiotoxic and may have additive effects during coadministration. Since trastuzumab has a half-life of approximately 28 to 38 days, it may persist in the circulation for up to 27 weeks after stopping treatment. Thus, the use of anthracyclines after stopping trastuzumab may also carry a higher risk of cardiac toxicity.

MANAGEMENT: Trastuzumab and cardiotoxic agents such as anthracyclines should not be used in combination except in settings where cardiac monitoring is possible. The use of anthracycline-based therapy should be avoided, if possible, for up to 7 months after stopping trastuzumab. If anthracyclines must be used sooner, the patient's cardiac function should be closely monitored.

References

  1. "Product Information. Herceptin (trastuzumab)." Genentech PROD (2001):
  2. Strasser F, Betticher DC, Suter TM "Trastuzumab and breast cancer." N Engl J Med 345 (2001): 996
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  4. Cerner Multum, Inc. "Australian Product Information." O 0
  5. "Product Information. DOXOrubicin Hydrochloride (doxorubicin)." Pfizer U.S. Pharmaceuticals Group (2015):
View all 5 references

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer